Systemic Janus kinase inhibitor treatment for vitiligo: An evidence-based review - 14/10/24
Doi : 10.1016/j.jaad.2024.08.066
Siddhartha Sood, HBSc a, Jaymie Varenbut, MMI a, Ahmed Bagit, BSc a, Jonah Perlmutter, BSc a, Khalad Maliyar, MD b, Muskaan Sachdeva, MD b, Abrahim Abduelmula, MD b, Jorge R. Georgakopoulos, MD b, Asfandyar Mufti, MD b, c, Vimal H. Prajapati, MD d, e, f, g, h, i, Jensen Yeung, MD b, c, i, j, ⁎ 
a Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
b Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
c Department of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
d Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
e Dermatology Research Institute, Calgary, Alberta, Canada
f Skin Health & Wellness Centre, Calgary, Alberta, Canada
g Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada
h Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada
i Probity Medical Research, Waterloo, Ontario, Canada
j Department of Dermatology, Women's College Hospital, Toronto, Ontario, Canada
∗Correspondence to: Jensen Yeung, MD, Division of Dermatology, Women's College Hospital, 76 Grenville St, 5th floor Toronto, Ontario M5S 1B2, CanadaDivision of DermatologyWomen's College Hospital76 Grenville St5th floorTorontoOntarioM5S 1B2Canada
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Monday 14 October 2024
Key words : evidence-based, JAK inhibitor, janus kinase inhibitor, systematic review, therapeutics, vitiligo
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable. |
|
| Prior presentations: Interim data were previously presented (oral presentation) at AAD 2024 in San Diego, California, USA. |
© 2024
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?